Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
SIGHT Stock Overview
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
GenSight Biologics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.12 |
52 Week High | €10.08 |
52 Week Low | €1.80 |
Beta | 2.82 |
1 Month Change | 1.44% |
3 Month Change | -37.52% |
1 Year Change | -76.58% |
3 Year Change | 48.11% |
5 Year Change | -69.08% |
Change since IPO | -74.01% |
Recent News & Updates
Shareholder Returns
SIGHT | FR Biotechs | FR Market | |
---|---|---|---|
7D | 6.3% | 0.4% | -2.9% |
1Y | -76.6% | -42.0% | -6.3% |
Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -39.9% over the past year.
Return vs Market: SIGHT underperformed the French Market which returned -18.8% over the past year.
Price Volatility
SIGHT volatility | |
---|---|
SIGHT Average Weekly Movement | 13.0% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in FR Market | 10.1% |
10% least volatile stocks in FR Market | 3.5% |
Stable Share Price: SIGHT is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SIGHT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 33 | Bernard Gilly | https://www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration.
GenSight Biologics Fundamentals Summary
SIGHT fundamental statistics | |
---|---|
Market Cap | €97.28m |
Earnings (TTM) | -€28.60m |
Revenue (TTM) | €7.70m |
12.6x
P/S Ratio-3.4x
P/E RatioIs SIGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SIGHT income statement (TTM) | |
---|---|
Revenue | €7.70m |
Cost of Revenue | €0 |
Gross Profit | €7.70m |
Other Expenses | €36.30m |
Earnings | -€28.60m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Jul 28, 2022
Earnings per share (EPS) | -0.62 |
Gross Margin | 100.00% |
Net Profit Margin | -371.43% |
Debt/Equity Ratio | 57.3% |
How did SIGHT perform over the long term?
See historical performance and comparisonValuation
Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SIGHT (€2.12) is trading below our estimate of fair value (€5.83)
Significantly Below Fair Value: SIGHT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SIGHT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.
PE vs Market: SIGHT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SIGHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SIGHT is overvalued based on its Price-To-Book Ratio (3x) compared to the FR Biotechs industry average (2.6x).
Future Growth
How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-8.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIGHT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SIGHT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SIGHT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SIGHT's revenue (47.9% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: SIGHT's revenue (47.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SIGHT's Return on Equity is forecast to be high in 3 years time
Past Performance
How has GenSight Biologics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-5.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SIGHT is currently unprofitable.
Growing Profit Margin: SIGHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SIGHT is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: SIGHT has a negative Return on Equity (-86.94%), as it is currently unprofitable.
Financial Health
How is GenSight Biologics's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SIGHT's short term assets (€64.1M) exceed its short term liabilities (€17.4M).
Long Term Liabilities: SIGHT's short term assets (€64.1M) exceed its long term liabilities (€17.1M).
Debt to Equity History and Analysis
Debt Level: SIGHT has more cash than its total debt.
Reducing Debt: SIGHT's debt to equity ratio has increased from 5.5% to 57.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SIGHT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SIGHT has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 1.2% each year.
Dividend
What is GenSight Biologics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
11.33%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SIGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SIGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SIGHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SIGHT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SIGHT has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Bernard Gilly (64 yo)
11.33yrs
Tenure
€2,438,633
Compensation
Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS.He co-founded Fovea Pharmaceutical...
CEO Compensation Analysis
Compensation vs Market: Bernard's total compensation ($USD2.62M) is above average for companies of similar size in the French market ($USD290.45K).
Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: SIGHT's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: SIGHT's board of directors are seasoned and experienced ( 10.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
GenSight Biologics S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: GenSight Biologics S.A.
- Ticker: SIGHT
- Exchange: ENXTPA
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €97.281m
- Shares outstanding: 45.93m
- Website: https://www.gensight-biologics.com
Number of Employees
Location
- GenSight Biologics S.A.
- 74, rue du Faubourg Saint-Antoine
- Paris
- Ile-de-France
- 75012
- France
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/24 00:00 |
End of Day Share Price | 2022/05/24 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.